Spectacle Lens Visual Acuity Assessments Study
Launched by SIGHTGLASS VISION, INC. · Dec 6, 2022
Trial Information
Current as of February 05, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Existing subject from the CYPRESS Extension study (CPRO-1802-002)
- • Ability to comply with study assessments
- • The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed coy of the form
- Exclusion Criteria:
- • Any current ocular infection, inflammation or irritation likely to affect vision
About Sightglass Vision, Inc.
SightGlass Vision, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative solutions for the treatment of myopia and other vision-related conditions. With a focus on developing cutting-edge optical devices and therapies, the company is committed to enhancing patient outcomes through rigorous research and evidence-based practices. Leveraging a team of experienced professionals and a robust clinical development framework, SightGlass Vision aims to bring transformative products to market that address the growing global challenge of myopia, ultimately improving the quality of life for individuals affected by vision impairments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburg, Kansas, United States
Longwood, Florida, United States
Salt Lake City, Utah, United States
New York, New York, United States
Raytown, Missouri, United States
Houston, Texas, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials